Individuality Clinical Trial
Official title:
Population Pharmacokinetic Modeling of Qishe Pill in Three Major TCM-defined Constitutional Types of Healthy Chinese Subjects: Study Protocol for a Phase I Clinical Trial
Qishe Pill (Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China), composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, has been developed and spread in use into clinical settings in 2009. As individualization has become the trend of modern medicine, a personalized medicine of Qishe Pill should be documented and practiced with various patients according to the ancient TCM system, a classification of personalized constitution type, which has been established to determine predisposition and prognosis to diseases as well as therapy and life-style administration. Therefore, we describe the population pharmacokinetic profile of Qishe Pill and compare its extent of metabolism in the 3 major Constitution Type (Qi-Deficiency, Yin-Deficiency and Blood-Stasis) to address major challenges of individualized and standardized Traditional Chinese Medicine into clinical practice.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | July 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 20 Years to 35 Years |
Eligibility |
Inclusion - Aged 20-35 - 18.5 kg/m2 =Body mass index (BMI) <23 kg/m2 - TCM-constitutionally typed as either the 3 major type Exclusion - History of impaired fasting glucose or diabetes mellitus (past history of diabetes or fasting blood glucose at screening =100 mg/dl) - History of liver disease (hepatitis, hepatic cirrhosis) or hepatic dysfunction (AST or ALT at screening =40 U/L) - History of renal dysfunction (creatinine at screening =1.2 mg/dl) - History of heart disease (heart failure, angina pectoris, myocardial infarction, arrhythmia) - History of malignant tumor - Having digestive disorders that can interfere with normal absorption of standard diet (gastritis, gastric ulcer, duodenitis, duodenal ulcer, etc.) - Smoking during the recent 3 months - Alcohol consumption 3 or more times a week during the recent 3 months - Women who were pregnant, intended to become pregnant, or breast- feeding - Medicated during the recent month for therapeutic or prophylactic purposes - Participating in another clinical trial |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Longhua Hospital, Shanghai University of TCM | Shanghai, | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai University of Traditional Chinese Medicine |
China,
Aker PD, Gross AR, Goldsmith CH, Peloso P. Conservative management of mechanical neck pain: systematic overview and meta-analysis. BMJ. 1996 Nov 23;313(7068):1291-6. — View Citation
Bovim G, Schrader H, Sand T. Neck pain in the general population. Spine (Phila Pa 1976). 1994 Jun 15;19(12):1307-9. — View Citation
Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet. 2002 Jul 20;360(9328):235. — View Citation
Cui X, Trinh K, Wang YJ. Chinese herbal medicine for chronic neck pain due to cervical degenerative disc disease. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006556. doi: 10.1002/14651858.CD006556.pub2. Review. — View Citation
EMEA. Strategies to identify and mitigate risks for first-in-human clinical trialswith investigational medicinal products; 2009, http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2009/09/WC500002988.pdf.
FDA/CDER. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; 2005, http://www.fda.gov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm078932.pdf.
Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, Aravagiri M, Schneider L, Bies RR. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008 Nov;66(5):629-39. doi: 10.1111/j.1365-2125.2008.03276.x. Epub 2008 Jul 31. — View Citation
Ge JR, Wang HM, Meng CX, Tong PJ. Effects of Qishe Pill, a compound traditional Chinese herbal medicine, on cervical radiculopathy: a randomized controlled trial for Phase III. Chinese Journal of New Drugs and Clinical. 2014(7):56-58.
Hsu H-Y: 1986 Oriental MateriaMedica. Long Beach, CA: Oriental Healing Arts Institute; 1986.
Johnson CL, Fulwood R, Abraham S, Bryner JD. Basic data on anthropometric measurements and angular measurements of the hip and knee joints for selected age groups 1-74 years of age. Vital Health Stat 11. 1981 Apr;(219):1-68. — View Citation
Liu M, Zhang N, Wang YJ, Zhang YQ, Zhou CJ. Technology research of Qishe Pill, a new medicine for cervical spondylosis. Lishizhen Med Mater Med Res. 2010(21):176-179.
Liu Mei, Zhang N, Wang YJ, Shi Q. Purification process research of major compound in Qishe Pill as Astragalus. Acta Chinese Medicine and Pharmacology. 2006(34):14-16.
Mäkelä M, Heliövaara M, Sievers K, Impivaara O, Knekt P, Aromaa A. Prevalence, determinants, and consequences of chronic neck pain in Finland. Am J Epidemiol. 1991 Dec 1;134(11):1356-67. — View Citation
Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. — View Citation
Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19. — View Citation
Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. — View Citation
van der Donk J, Schouten JS, Passchier J, van Romunde LK, Valkenburg HA. The associations of neck pain with radiological abnormalities of the cervical spine and personality traits in a general population. J Rheumatol. 1991 Dec;18(12):1884-9. — View Citation
Wang Q. Classification of the nine basic TCM constitutional type and based expression and diagnosis. Journal of Beijing University of Traditional Chinese medicine. 2005.1-8
Zhang WJ, Hufnagl P, Binder BR, Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappaB activation and adhesion molecule expression. Thromb Haemost. 2003 Nov;90(5):904-14. — View Citation
Zhang YQ, Liu XH, Zhang N, Liu M. Quality standard research of Qishe Pill. Lishizhen Med Mater Med Res. 2008(19): 977-979.
Zhu YB, Wang Q, Xue HS, Origasa H. Preliminary assessment on performance of constitution in Chinese medicine questionnaire. ZhongGuo Lin Chuang Kang Fu 2006; 10 (3): 15-17.
* Note: There are 21 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The Constitution in Chinese Medicine Questionnaire (CCMQ) | Two qualified traditional Chinese medical doctors licensed by the Chinese government determine the constitution according to CCMQ | During screening in the recuitment | No |
Other | The Constitution in Chinese Medicine Questionnaire (CCMQ) | Two qualified traditional Chinese medical doctors licensed by the Chinese government determine the constitution according to CCMQ | 2880 min after dosing | No |
Other | Laboratory measures and clinical assessment | These parameters including blood count, electrolytes, renal and liver function parameters, blood lipids, age, gender, history of smoking, blood pressure, weight (kg), and height (meters) will be obtained for all subjects. | During screening in the recuitment | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | Dosing(0 hour) | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 15 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 30 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 45 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 60 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 90 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 120 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 150 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 180 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 240 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 360 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 480 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 600 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 720 min after dosing | No |
Primary | Plasma concentrations of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 1440 min after dosing | No |
Primary | Plasma concentration of Qishe Pill | 5 ml blood samples for pharmacokinetic analysis | 2160 min after dosing | No |
Primary | Plasma sampling of Qishe Pill for pharmacokinetic analysis | 5 ml blood samples for pharmacokinetic analysis | 2880 min after dosing | No |
Primary | Vital signs | body temperature, heart rate and blood pressure | Dosing(0 hour) | Yes |
Primary | Vital signs | body temperature, heart rate and blood pressure | 180 min after dosing | Yes |
Primary | Vital signs | body temperature, heart rate and blood pressure | 720 min after dosing | Yes |
Primary | Vital signs | body temperature, heart rate and blood pressure | 1440 min after dosing | Yes |
Primary | Vital signs | body temperature, heart rate and blood pressure | 2160 min after dosing | Yes |
Primary | Vital signs | body temperature, heart rate and blood pressure | 2880 min after dosing | Yes |
Primary | ECG monitoring | Electrocardiograms (ECGs) | Dosing(0 hour) | Yes |
Primary | ECG monitoring | Electrocardiograms (ECGs) | 180 min after dosing | Yes |
Primary | ECG monitoring | Electrocardiograms (ECGs) | 720 min after dosing | Yes |
Primary | ECG monitoring | Electrocardiograms (ECGs) | 1440 min after dosing | Yes |
Primary | ECG monitoring | Electrocardiograms (ECGs) | 2160 min after dosing | Yes |
Primary | ECG monitoring | Electrocardiograms (ECGs) | 2880 min after dosing | Yes |
Primary | Number of Participants with Adverse Events | The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug. | Day 1 of drug administration and blood sampling | Yes |
Primary | Number of Participants with Adverse Events | The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug. | Day 2 of drug administration and blood sampling | Yes |
Primary | Number of Participants with Adverse Events | The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug. | Day 3 of drug administration and blood sampling | Yes |
Primary | Number of Participants with Adverse Events | Subjects will be requested to return to the study unit 4 d after drug administration and blood sampling for a follow-up visit. | 4 days after drug administration and blood sampling | Yes |
Primary | Peak Plasma Concentration (Cmax) of Qishe Pill in low dosage | The maximum plasma concentration | 4 days after drug administration and blood sampling | No |
Primary | Peak Plasma Concentration (Cmax) of Qishe Pill in medial dosage | The maximum plasma concentration | 4 days after drug administration and blood sampling | No |
Primary | Peak Plasma Concentration (Cmax) of Qishe Pill in high dosage | The maximum plasma concentration | 4 days after drug administration and blood sampling | No |
Primary | The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in low dosage | The time to maximum concentration | 4 days after drug administration and blood sampling | No |
Primary | The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in medial dosage | The time to maximum concentration | 4 days after drug administration and blood sampling | No |
Primary | The Time to Peak Plasma Concentration (Tmax) of Qishe Pill in high dosage | The time to maximum concentration | 4 days after drug administration and blood sampling | No |
Primary | Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in low dosage | The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule. | 4 days after drug administration and blood sampling | No |
Primary | Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in medial dosage | The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule. | 4 days after drug administration and blood sampling | No |
Primary | Area under the Plasma Concentration versus Time Curve (AUC) of Qishe Pill in high dosage | The area under the plasma concentration-time curve (AUC) will be calculated using the linear trapezoidal rule. | 4 days after drug administration and blood sampling | No |
Primary | The distribution volume (DF) of Qishe Pill in low dosage | The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant. | 4 days after drug administration and blood sampling | No |
Primary | The distribution volume (DF) of Qishe Pill in medial dosage | The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant. | 4 days after drug administration and blood sampling | No |
Primary | The distribution volume (DF) of Qishe Pill in high dosage | The distribution volume (DF) will be calculated by Dose/AUC/ke. ke is the elimination rate constant. | 4 days after drug administration and blood sampling | No |
Secondary | Deep phenotyping with genomics and functional genomics approaches | 3 ml blood samples for genomic variants analysis. The cytochrome P450 gene family, such as CYP1A1, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5 , etc, will be chosen as the target objective. | Dosing(0 hour) | No |
Secondary | Deep phenotyping with genomics and functional genomics approaches | 3 ml blood samples for genomic variants analysis. The cytochrome P450 gene family, such as CYP1A1, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5 , etc, will be chosen as the target objective. | 2880 min after dosing | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02478021 -
Effects of Hydrocortisone on Social Cognition and Memory
|
N/A | |
Completed |
NCT02906306 -
Effects of Individual and Group Occupational Therapy on General Self-Efficacy, Psychological Well-Being, Personal Independence and Occupational Therapy in Older Adults
|
N/A | |
Completed |
NCT01699893 -
Genetic & Environmental Determinants Of Immune Phenotype Variance: Establishing A Path Towards Personalized Medicine
|
N/A | |
Completed |
NCT03905993 -
Milieu Intérieur Collection - Genetic & Environmental Determinants Of Immune Phenotype Variance
|
||
Terminated |
NCT02296359 -
Vaccination Response in Individual Monozygotic Twins
|
N/A | |
Terminated |
NCT02654704 -
Vaccination Responses in Young and Older Adults
|
||
Recruiting |
NCT05201534 -
Interventions in Mathematics and Cognitive Skills
|
N/A | |
Completed |
NCT02478034 -
Effects of Mineralocorticoid Receptor Stimulation on Cognition
|
N/A | |
Completed |
NCT02071485 -
Non-Invasive Brain-Computer Interface for Virtual Object Control
|
N/A | |
Completed |
NCT02102191 -
Acute Physiological Effects of Electronic Sigarette vs Cigarette Smoking
|
N/A | |
Recruiting |
NCT03147443 -
Evaluating the Effects of Traditional Chinese Medicine by N-of-1 Trials
|
Phase 4 | |
Completed |
NCT01748071 -
The Realtime Detection for Individual Variation of Analgesic :A Comparison of Sufentanil vs Fentanyl
|
N/A | |
Completed |
NCT02070614 -
Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption
|
N/A | |
Recruiting |
NCT04601792 -
A Series of N-of-1 Trials of Traditional Chinese Medicine Based on Bayesian Method
|
Phase 4 | |
Completed |
NCT02768636 -
Can Omega-3 Improve Heart Rate Variability Measurement?
|
Phase 4 | |
Completed |
NCT02761031 -
Perioperative Heart Rate Variability Analysis in Realtime
|
||
Completed |
NCT01868152 -
The Realtime Detection for Prediction of Opioid Analgesic
|
N/A |